同义名 :	PB; Vercyte
	CAS号 :	54-91-1
	货号 :	A163585
	分子式 :	C10H16Br2N2O2
	纯度 :	98%
	分子量 :	356.05
	MDL号 :	MFCD00866372
	存储条件：	Pure form Inert atmosphere, 2-8°C In solvent -20°C:3-6个月-80°C:12个月
	溶解度 :	-
	动物实验配方：

生物活性

描述

Pipobroman is a bromide derivative of piperazine and acts as an alkylating agent. Pipobroman plays its role by inhibiting DNA and RNA polymerase or by reducing pyrimidine nucleotide incorporation into DNA. Pipobroman can be used for the cancer research, including polycythemia vera, myeloproliferative neoplasm, and AML et.al[3]. The low cumulative 10-year risk of thrombosis, leukaemia and solid tumours indicates that pipobroman is an adequate treatment for patients with high risk ET (Essential thrombocythaemia)[4].

临床研究
NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT01243944	Polycythemia Vera	Phase 3	Completed	-	-
NCT02038036	Polycythemia Vera	Phase 3	Active, not recruiting	April 8, 2020	-
NCT01243944	-		Completed	-	-

实验方案
	1mg	5mg	10mg
1 mM 5 mM 10 mM	2.81mL 0.56mL 0.28mL	14.04mL 2.81mL 1.40mL	28.09mL 5.62mL 2.81mL

参考文献

[1]Kiladjian JJ, Chevret S, et al. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol. 2011 Oct 10;29(29):3907-13. [2]Passamonti F, Lazzarino M. Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman. Leuk Lymphoma. 2003 Sep;44(9):1483-8. [3]Cassius C, Pages C, Roux J, Lhote R, Lavocat R, Réa D, Bagot M, Mourah S, Battistella M, Lebbé C, Dumaz N. Association of Vemurafenib and Pipobroman Enhances BRAF-CRAF Dimerization in Squamous Cell Carcinoma. J Invest Dermatol. 2016 Jun;136(6):1302-1305 [4]Passamonti F, Malabarba L, Orlandi E, Pascutto C, Brusamolino E, Astori C, Baratè C, Canevari A, Corso A, Bernasconi P, Cazzola M, Lazzarino M. Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. Br J Haematol. 2002 Mar;116(4):855-61